New from #EHA2026 shows promising results for transfusion-dependent thalassemia patients! An alternating weekly regimen of deferasirox for 3 days and deferiprone for 4 days significantly improved: 📉 Serum ferritin levels (P=.006) ❤️ Cardiac T2* MRI values (P=.005) 🔗 https://bit.ly/4wnxCdY

🚨 New Guidelines for Pediatric #AML: An international expert panel has released updated consensus recommendations for managing AML!🩸 Key takeaways emphasize the power of NGS genomic testing, tailored risk-stratification, and targeted therapies to improve outcomes and QoL. 🔗 https://bit.ly/4gBl4uC

More remarkable research from this year's #EHA2026 Congress! 🚨 The Phase 3 MonumenTAL-3 trial for Relapsed/Refractory Multiple Myeloma (#RRMM) found adding the novel T-cell engager talquetamab to daratumumab ± pomalidomide significantly improves PFS. 🔗 Study details: https://bit.ly/4g1MQAq

Living with #HereditaryAngioedema means facing unpredictable, painful swelling episodes. The final long-term results from the CHAPTER-1 study show that deucrictibant, safely reduces HAE attacks by an average of 92%! 🧬💪 🔗Read more about this remarkable study, here: https://bit.ly/4eBIEEX

🆕 New research from the #EHA2026 Congress! Long-term results from the Phase 3 AGILE trial are reinforcing ivosidenib + azacitidine as a first-line standard of care for newly diagnosed, intensive chemo-ineligible IDH1-mutant #AML patients 📊🩸 For more study details: 🔗 https://bit.ly/4xLt5TZ

Every milestone and clear scan is a victory shared. This #NationalCancerSurvivorsMonth, we celebrate our resilient blood cancer survivors and the incredible clinicians who walk alongside them🩸✨ To our #HemOnc clinicians: thank you for your tireless dedication, expertise, and heart!❤️🩺

Latest clinical trial update: Romiplostim helps 84.4% of GI cancer patients maintain full-dose, on-time chemotherapy by effectively treating chemotherapy-induced thrombocytopenia (#CIT) 🩸💪. 📊 Research originally published in @nejm.org 🔗 Read our story here: https://bit.ly/4uSo7SL

New phase 3 clinical trial results are in for Core-Binding Factor Acute Myeloid Leukemia (#CBFAML) 🩸🧬 Adding dasatinib to intensive chemotherapy failed to improve event-free or overall survival outcomes for adult patients, regardless of age or KIT mutation status. 🔗 https://bit.ly/43KWSOZ

For years, hemophilia care focused on strict activity restriction. Today, we know inactivity accelerates joint damage. With modern prophylaxis, structured exercise is a safe, effective way to build muscle and protect joints. Read the full feature: https://bit.ly/4vWeRy0 📸 Getty Images

New data from the JACKPOT26 trial shows that golidocitinib maintenance therapy significantly extends remission for peripheral T-cell lymphoma (#PTCL): A major step forward in preventing relapse for a tough-to-treat cancer. 👇 https://bit.ly/3Sb328s

A major shift in Hodgkin Lymphoma care! 🧬 A Phase 2 trial shows response-adapted nivolumab (#PD1 inhibitor) is a highly effective, low-toxicity first salvage therapy. 🔗 https://bit.ly/4xMy2vU #HodgkinLymphoma #HemOnc

A major win for pediatric leukemia research! 🩺✨ A new multicenter trial published in Blood shows that low-dose induction chemotherapy is noninferior to standard-dose treatment for children with acute myeloid leukemia (#AML).🔬 🔗 https://bit.ly/4uINcQ7 #Leukemia

New phase 2 PRIMO trial results show promising response rates for duvelisib in relapsed/refractory peripheral T-cell lymphoma! 🩺✨ Highlights: 🔹 ORR of 48% (33.3% CRR) 🔹 The AITL subtype saw the greatest benefit, with an ORR of 62.2% and a median OS exceeding 18 months! 🔗 https://bit.ly/4ejv8pm

Traditional blood tests may be missing iron deficiency in kids. 🧒 Current guidelines look for ferritin levels ≤ 15 μg/L, but new physiological data shows a child’s health can be affected much earlier—when levels drop below 24 μg/L. 📊 Read more here: https://bit.ly/4vLaLZp

Achieving a complete response with CAR-T cell therapy leads to highly durable, long-term remission for large B-cell #Lymphoma patients. Reaching CR remains the strongest predictor of lasting survival.📊 🔗 Get the full story here: https://bit.ly/4okJc6O

A new EBMT study compares alemtuzumab and ATG for GVHD prophylaxis in older #ALL patients. Both show similar 2-year survival and low complication rates after reduced-intensity conditioning. 🔗 https://bit.ly/4o6pmMl #Leukemia

Real-world data from #ASCO26 shows an alternating lower-intensity regimen (CLAD/LDAC/VEN and AZA/VEN) is effective and feasible for older AML patients in a community hospital setting, yielding a 60% CRc rate in the frontline. 🔗 https://bit.ly/43isKdw

🆕 New pooled data from 3 clinical trials presented at #ASCO26 Favorable long-term safety profile for liso-cel (CAR-T) as a 2nd-line+ treatment for Large B-Cell Lymphoma. Cytopenias and transfusion needs fell sharply after the initial months. 📉 🔗 https://bit.ly/43Wv0au

Adding tafasitamab to DA-EPOCH chemo improves early MRD-negativity for newly diagnosed Ph− B-ALL patients.🩺📈#ASCO26 🗝️ Key Results: 🔹 41% MRD-negativity (≤0.01%) at Cycle 1 🔹 71% MRD-negativity at Cycle 4 🔹 76% morphologic complete response rate 🔗 https://bit.ly/4uW1TQq

🆕 Phase 2/3 data at #ASCO26 shows calaspargase pegol (Cal-PEG) achieves sustained asparagine depletion in adults with newly diagnosed Ph- ALL. ⚠️ Efficacy was high, but safety concerns remain: 73.8% had grade 3/4 treatment-related adverse events, and 35.7% discontinued. 🔗 https://bit.ly/3RTCqZC

📊 Real-world data from #ASCO26 Bispecific antibodies (#BsAbs) are associated with lower early toxicity and fewer ICU admissions than CAR-T therapy for patients with #DLBCL and #FollicularLymphoma. 🔗 https://bit.ly/4ecpeq6

DOAC vs. Warfarin for patients with IBD and VTE? New data in Blood Advances shows DOACs lower serious bleeding risk (8.2 vs 13.6 events per 100 person-years) with similar recurrent VTE protection. 🩸📉 Read more about this study here: https://bit.ly/3PZHF9e #Hematology #IBD #Thrombosis

New EBMT registry data shows both yield comparable efficacy & safety for #ALL patients receiving reduced-intensity conditioning HCT. 📊✨ At the 2-year mark, the study found no significant differences in: ✅ Leukemia-free & OS ✅ Relapse incidence 🔗https://bit.ly/4o6pmMl #Leukemia

New from #ASCO26! 🚨 A Cleveland Clinic study found that when Black patients with newly diagnosed #MultipleMyeloma receive equal access to modern triplet or quadruplet therapies, 5-year survival outcomes are comparable to White patients. 🩺📊 🔗https://bit.ly/4fYIWIg

Big news emerging from the #ASCO26 Annual Conference happening this week! 🩺 Data from the landmark Phase 3 IRAKLIA trial highlights a major advancement in treatment safety and convenience for patients with multiple myeloma. 🔗 https://bit.ly/4x5Qsav

🆕 From #ASCO26 reported on by Hematology Advisor: Luspatercept Superior to Epoetin Alfa for Low-Risk MDS Read the presentation highlights here: 🔗 https://bit.ly/3PD0pLT

🆕 From #ASCO26 reported on by Hematology Advisor: Luspatercept Superior to Epoetin Alfa for Low-Risk MDS Read the presentation highlights here: 🔗 https://bit.ly/3PD0pLT

Final analysis from the Phase 3 CEPHEUS trial establishes the anti-CD38 quadruplet regimen as a powerful frontline standard for transplant-ineligible (TIE) newly diagnosed multiple myeloma. 🩺 Read the full clinical review on this #ASCO26 presentation: 👇 https://bit.ly/4obfXmQ #MultipleMyeloma

Practice-affirming data from the Phase 3 CEPHEUS trial! 🚨 Final analysis confirms that adding subcutaneous daratumumab to a VRd backbone (DVRd) significantly deepens responses and extends survival in transplant-ineligible (#TIE) NDMM. ✨ Read more on this #ASCO26 study: https://bit.ly/4obfXmQ

New from #ASCO26🚨 Maternal mortality rates are higher for pregnant women diagnosed with myeloproliferative neoplasms #MPNs. Research from the 2026 ASCO Annual Meeting explored the risks and warning signs. Read the full story here: https://bit.ly/3QcFwXY

Clinical update from #ASCO26: Chidamide + CHOP shows promising frontline activity for patients with T-follicular helper (TFH) phenotype peripheral T-cell lymphoma (#PTCL). 🩸💊 Full analysis for oncologists: https://bit.ly/4al9tf8 #ASCO2026 #lymphoma

Updated clinical data on tisagenlecleucel for R/R B-cell acute lymphoblastic leukemia reinforces its role as a potentially curative option while emphasizing the need for proactive risk management. 🧬🔬 Read our coverage of this #ASCO26 presentation here: https://bit.ly/4e0R34x #Leukemia #Hematology

The latest from #ASCO26! ✨ New clinical data highlights the evolving role of selinexor in the management of #AML! 🧬 Recent insights look at how this XPO1 inhibitor is being utilized to improve clinical outcomes and tackle treatment resistance. Full article: https://bit.ly/4uKwssz #ASCO2026

🆕 #ASCO26! 🚨 The Phase 3 SUCCESSOR-2 trial shows that adding oral mezigdomide to Kd nearly doubles progression-free survival in RRMM. 📈 Median PFS: 18.0 mos vs 8.3 mos 📉 52% reduction in risk of progression/death (HR 0.48) A major leap for triple-class exposed patients. 🧬 🔗 https://bit.ly/4u7KJhA

🚨 Breaking from #ASCO26: The Phase 2 ERASMM trial shows elranatamab monotherapy is highly effective for high-risk smoldering myeloma! 🔹 92% Overall Response Rate 🔹 72% Complete Response 🔹 90% MRD negativity Is early intervention the new standard? 🧬 🔗 https://bit.ly/4dFOVQX #MultipleMyeloma

Fertility preservation is a cornerstone of Hodgkin Lymphoma survivorship care. 🧬 New data highlights the variable gonadotoxicity of modern regimens (ABVD vs. BrECADD) and the importance of early intervention. Full clinical feature: 🔗 https://bit.ly/4dRrbbr

GVHD remains a common and potentially lethal complication for patients undergoing allogeneic HCT. Discover the latest insights on managing this complex condition and improving patient outcomes. 🩺🩸 Read more: https://bit.ly/43AmJZy #HemOnc #GVHD #HCT

🩺Next-gen BTK inhibitors like zanubrutinib are showing improved safety and durability over ibrutinib in the treatment of CLL. Key takeaways: ✅ Enhanced progression-free survival ✅ Lower risk of atrial fibrillation/cardiovascular toxicities ✅ Better long-term tolerability 🔗 https://bit.ly/4wSUv9V

The ASCO 2026 insights are in! 🧪 From breakthroughs in CAR-T cell therapy to new data on managing hematologic malignancies, this year's meeting is redefining the standard of care. 📈 Get the full report on the most impactful studies here: https://bit.ly/4vcHmHf #ASCO26

Attending the 2026 @ascopost.bsky.social Annual Meeting? Join us and Haymarket Media at this upcoming event in Chicago where our all-star panel will discuss how AI is transforming the patient-provider dialogue in cancer care! Link to RSVP: https://bit.ly/4uQql5A #ASCO2026

Is CAR T-cell therapy becoming a definitive cure? 🩸 The long-term outlook for hematologic cancers is improving, but challenges like antigen escape and late toxicities remain. Get the latest data on CAR-T durability and the path forward: https://bit.ly/4uotiKQ #HemOnc

Recent data from the 2026 ASPHO Conference found that HLA-matched sibling donor HCT done prior to adolescence demonstrated promising safety and efficacy outcomes among patients with sickle cell disease.🧬 🔗 Dive into this comprehensive report: https://bit.ly/49aABx3 #SCD #SickleCellDisease

New data shows that shortened outpatient treatment for #AcuteLeukemia is not only feasible but offers significant cost savings for healthcare systems. 🏥📉 🔗 Learn more about the safety and implementation of this model: https://bit.ly/4nABXHc #Leukemia #OncSky

Can papaya leaf extract actually improve platelet counts? 📈🌿 New data explores how #CPLE accelerates recovery in #thrombocytopenia by targeting gene expression in megakaryocytes. A promising, low-toxicity adjunct for the clinic. 🧪📉 More here: https://bit.ly/4eQgiIZ #HemOnc #Chemotherapy

Did you know women were not generally considered in clinical trial research until the 1990s? This #ClinicalTrialsAwarenessMonth we are highlighting women's rolls in clinical trials! Read the history and impact of women in #clinicaltrials here: https://bit.ly/4wy1FQS #Oncology #HemOnc

🆕 New from @TheLancetHaem: The use of oral deucrictibant may benefit patients with hereditary angioedema. Read more about the findings here; https://bit.ly/3PqTLIb #angioedema #BleedingDisorders #Hematology #oraldeucrictibant

Attending the 2026 @ascocancer.bsky.social Annual Meeting? Join us and Haymarket Media US at this upcoming event in Chicago where our all-star panel will discuss how AI is transforming the patient-provider dialogue in cancer care! Link to RSVP: https://bit.ly/4uQql5A

ICYMI❗ From The 2026 ASPHO Conference Declining rates of Rh-associated HDF means lack of clinical exposure leading to delayed diagnoses and subsequent undertreatment. E-learning curriculum has shown to improve #HDFN outcomes 🧬📈 Read more: https://bit.ly/4wsHq75 #ASPHO2026 #PedHem

Is the myristoyl pocket the new key to #CML sequencing? 🔑🧬 New data highlights the benefits of #asciminib—the first STAMP inhibitor. By avoiding the ATP-binding site, it overcomes resistance while minimizing off-target toxicities. 📉 Molecular insights: https://bit.ly/3PEoCkL

Targeting the epigenome and proteasome in #Leukemia. 🧬🔬 New Phase 1 data shows promise for the #Bortezomib + #Vorinostat combo in acute leukemia. Synergistic inhibition may be key to tackling refractory disease. 📉 Full story: https://bit.ly/4fcngIk #AML #CancerCare #HemOnc